Cancer

SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $23.6 Million in Gross Proceeds

NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a…

3 months ago

FibroBiologics Announces Positive IND-Enabling Updates Demonstrating Potential of Fibroblast Spheroids in Chronic-Relapse Psoriasis Treatment

Pilot studies underway to advance IND-enabling preclinical developmentHOUSTON, Sept. 11, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a…

3 months ago

Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225

Supports Clinical Development of CLR 121225, Actinium-Labeled Compound for the Treatment of Solid TumorsFLORHAM PARK, N.J. and GARCHING, Germany and…

3 months ago

Cosmos Health Expands Presence in the $7 Billion GCC Nutraceuticals Market, Signs Distribution Agreement with Scientific Pharmacy for Sky Premium Life in Oman, Including Initial Purchase Order of 42,000 Units

CHICAGO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global…

3 months ago

Biodesix Announces One-for-Twenty Reverse Stock Split

LOUISVILLE, Colo., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX) (“Biodesix” or the “Company”), a leader in personalized…

3 months ago

Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204’s Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration

New Positive Preclinical Data Shows Succesful Drug Distribution to Liver, Peritoneum, and Lung with Measurable Reductions in Tumor Burden at…

3 months ago

RadioMedix and Vect-Horus Announce First Patient Dosed in Exploratory Clinical Study of 203Pb-RMX-VH-PIB for Glioblastoma Multiforme and Pancreatic Ductal Adenocarcinoma

Marks a significant milestone in ongoing collaboration between RadioMedix and Vect-Horus to advance innovative Theranostic radiopharmaceuticals to address unmet needs…

3 months ago

GenVivo Strengthens Oncology Leadership with Appointment of Noriyuki Kasahara, M.D., Ph.D., as Chief Scientific Officer

Scientific Advisory Board member, Dr. Noriyuki Kasahara, appointed Chief Scientific Officer of GenVivo, to accelerate the achievement of major clinical…

3 months ago

Scancell reports Business Update and Financial Results for the Year Ended 30 April 2025

NOTTINGHAM, United Kingdom, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP), the developer of ImmunoBody® and Moditope®…

3 months ago

Bioptimus Assembles Elite Scientific Advisory Board to Build Next-Gen AI Models for Biology

Eight internationally renowned experts join Bioptimus to pioneer large-scale foundation models that will transform science and medicine PARIS, Sept. 11,…

3 months ago